An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy

Trial Profile

An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Fluorouracil; Panitumumab
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 Mar 2018 to 31 Mar 2018.
    • 31 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Mar 2018.
    • 11 Oct 2016 Results (n=134) of efficacy, safety and circulating tumor DNA (ctDNA) analysis presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top